In Plain English
Sermorelin is the front section of the body’s own growth hormone releasing hormone — the shortest piece that still does the job. Because it prompts your pituitary rather than supplying growth hormone directly, your natural feedback controls stay in the loop, which is generally regarded as the safer architecture. It clears quickly, so it produces a pulse rather than a sustained elevation.
What people use it for. Growth hormone support for recovery, sleep and body composition — the same goals as CJC-1295 and Ipamorelin.
What to know before you buy. Sermorelin's appeal is its history: it was an approved medicine for years and was pulled for business reasons, not because anything went wrong with it. That is genuine reassurance about the molecule. The catch is that it clears very fast, which is why the newer modified analogues exist, and the approval evidence was in children with a growth hormone deficiency — not adults looking for body composition changes.
What It's Used For
| Goal | What that rests on |
|---|---|
| Growth hormone support | Prompts your own pituitary; feedback controls stay in place |
| Recovery and sleep | Commonly reported across the GHRH class |
| Regulatory history | Was an approved medicine (Geref) and was withdrawn for commercial reasons, not safety findings |
| Natural pulse pattern | Very short half-life produces a pulse rather than sustained elevation |
The left column lists goals people commonly pursue with this compound; the right column states what that rests on. These are described uses and research findings, not proven outcomes or treatment claims. Individual results vary and no outcome is promised.
Pricing & Sizes
Ships sealed and lyophilized — stable for years at room temperature, reconstitute before use, or ask and it will be reconstituted free at the volume shown below. Free shipping on every order, no minimum. Third-party COA available for every batch — HPLC purity and mass spec verification.
Reconstitution — bacteriostatic water: 10mg vial at 2mL = 5mg/mL, so 10 units on a 100-unit syringe draws 0.5mg. Concentrations are arithmetic from vial content and diluent volume, not a dosing recommendation.
Text To OrderAt a Glance
- Class
- Synthetic analogue of the first 29 amino acids of growth hormone releasing hormone (GHRH 1-29)
- Mechanism
- Stimulates pituitary GHRH receptors, prompting release of the body’s own growth hormone
- Regulatory history
- Approved as Geref for paediatric growth hormone deficiency; discontinued in 2008 for commercial reasons, not on safety grounds
- Current status
- No longer an approved product in the US; widely available through compounding
- Half-life
- Short — roughly 10 to 20 minutes, producing a pulse rather than sustained elevation
- Regulatory (US)
- Not on the July 2026 PCAC agenda; status unaffected by that hearing
- Format
- 10mg vial
Regulatory status
Sermorelin was an FDA-approved drug (Geref) and was withdrawn from the US market in 2008 for commercial reasons rather than safety findings — a meaningful distinction. It is no longer an approved product, and material sold today is not the former approved drug. Sermorelin was not on the July 2026 PCAC agenda and its status is unchanged by that hearing.
How It Compares
| Sermorelin | CJC-1295 no DAC | Tesamorelin | |
|---|---|---|---|
| Structure | GHRH 1-29 | GHRH 1-29, modified for stability | GRF 1-44, stabilised |
| Half-life | ~10-20 min | ~30 min | Longer |
| Approval | Former (Geref, to 2008) | None | Current (Egrifta) |
| Evidence | Approval-era paediatric data | Early-phase PK data | Completed phase III |
Sermorelin’s advantage over the newer analogues is that it once cleared a regulatory review, which none of the unapproved GHRH peptides have. Its disadvantage is a very short half-life, which is largely why the modified analogues were developed.
Evidence Position
The approval-era evidence concerned paediatric growth hormone deficiency — a defined clinical population with a defined endpoint. That is real regulator-reviewed evidence, and it does not extend to use in healthy adults for body composition, recovery or anti-ageing, which was not what the approval studied.
As with the whole GHRH class, sermorelin reliably raises growth hormone. Whether that elevation produces meaningful outcomes in healthy adults is not established by controlled trials. IGF-1 is the appropriate marker for confirming pharmacological activity.
The bottom line
The GHRH analogue with the longest regulatory track record and the shortest duration of action. Its former approval is genuine reassurance about the mechanism and about safety in the studied population — it is not evidence for the uses it is now typically sold for.
Also in the Range
Compare with CJC-1295 + Ipamorelin (two pathways rather than one) and Tesamorelin (the only one in the range with a current FDA approval behind the molecule).